Corvus raises $75M in series B round

Corvus Pharmaceuticals Inc. (Burlingame, Calif.) raised $75 million in a series B round led by new investor Rock Springs Capital Management. New investors Fidelity; Blackrock; T. Rowe Price; Jennison Associates; Roche Venture Fund; Cormorant Asset Management; Sphera Funds Management; venBio; and Cowen Private Investments also participated, as did existing investors OrbiMed; Novo Ventures; and Adams Street Partners.

Corvus plans to begin a Phase Ib trial in 1Q16 of its oral immune checkpoint inhibitor alone and in combination with an undisclosed checkpoint inhibitor to treat various cancers. The company declined to provide details. ...